Manages schizophrenia. ANDA 90453, held by Epic Pharma LLC. Molindone Hydrochloride.
As of Nov 16, 2026, ANDA 90453 (Molindone Hydrochloride), held by Epic Pharma LLC, was first approved by FDA on Mar 20, 2015, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Molindone Hydrochloride Tablets, USP are indicated for the management of schizophrenia. The efficacy of Molindone Hydrochloride Tablets, USP in schizophrenia was established in clinical studies which enrolled newly hospitalized and chronically hospitalized, acutely ill, schizophrenic patients as subjects.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 20, 2015 | Original application | Approved | None posted |
| Molindone Hydrochloride5MG · tablet;oral | Molindone Hydrochloride | Rx |
| Molindone Hydrochloride10MG · tablet;oral | Molindone Hydrochloride | Rx |
| Molindone Hydrochloride25MG · tablet;oral | Molindone Hydrochloride | Rx |
| Jan 22, 2025 | Supplement 11Labeling · Standard review | Approved | None posted |
| Feb 23, 2017 | Supplement 4Labeling · Standard review | Approved | None posted |
| Mar 20, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters